The "Copper Wall Iron Wall" innovative therapy through the "King of Cancer" achieved a 59% objective mitigation rate.

Pancreatic cancer is known as the "King of Cancer" because of its high fatality rate, the reason is that in addition to pancreatic cancer is difficult to find, the patient was diagnosed at a late stage, pancreatic cancer for a variety of treatments have a high resistance to one of the reasons.
One reason for the high resistance of pancreatic cancer is that pancreatic cancer cells are able to transform the substitins around the tumor, allowing them to form barriers to drug penetration, a "copper wall" that makes it difficult for chemotherapy drugs to penetrate inside the tumor and kill the cancer cells in it.
at this year's ESMO Virtual Conference, a company called Cend Therapeutics announced positive Phase 1 clinical results for patients with metastatic pancreatic cancer using its innovative treatment CEND-1 in combination with gistabin and albumin yew alcohol.
trial results showed that the combination therapy reached a total remission rate of 59% in 29 patients.
, also known as iRGD, is a peptide that binds to neuropilin.
neurobacterial hair protein is one of the highly expressed proteins on pancreatic cancer cells, which, when combined with iRGD, mediates the cell's internal swallowing and produces delivery vesicles.
these vesicles can be used with iRGD to transfer anti-cancer drugs from the blood to tumor tissue, thereby enhancing the lethal effect of anti-cancer drugs.
In a Phase 1 clinical study, CEND-1 and the 3-combination therapy consisting of gistabin and albumin yew alcohol achieved a total remission rate of 59% in the treatment of patients with metastatic pancreatic cancer, with one patient achieving complete remission, 16 patients partially remission, 10 patients in stable condition and disease control rate reaching 83%.
, the total remission rate of clinical trials that historically supported the approval of albumin yew alcohol was 23%.
the clinical trial ended early because of COVID-19, but the researchers say the positive results are worth continuing with the validation trial.
: Cend Therapeutics Announcs Presentation and Abstract Publication at 2020 European Society for Medical Oncology (ESMO) Meeting. Retrieved September 18, 2020, from 1528P - Phase I trial of the first-in-class agent CEND-1 in-group with gemcitabine and nab-paclitel patients with metastatic pancre cancer. Retrieved September 18, 2020, from Esmo 2020 - private group claims early but impressive pancreatic win. Retrieved September 18, 2020, from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .